Celecoxib-Induced Modulation of Colon Cancer CD133 Expression Occurs through AKT Inhibition and Is Monitored by ⁸⁹Zr Immuno-PET

Figure 4

Effects of celecoxib on HT29 cell signaling pathways. (a) ⁸⁹Zr-CD133 IgG binding. (b) Immunoblots and quantified band intensities of CD133 (left), HIF-1α (middle), and p-AKT (right) after 24 hours of treatment with graded doses of celecoxib. (c) Immunoblots and quantified band intensities of total cellular CD133 and p-AKT and cytosolic p-IκBα. Bars are of % controls obtained from triplicate (A binding and C) or duplicate samples per group (A immunoblots and B). Band intensities are corrected by β-actin (CD133 and p-IκBα) or t-AKT (p-AKT). , ^†, and ^‡, compared to controls.

(a)

(b)

(c)